MingSight Pharmaceuticals
Phase 1/2MingSight Pharmaceuticals is a clinical stage company focused on the development of a new generation of selective inhibitors of protein kinase C (PKC) for the treatment of diseases with high unmet medical needs.
Founded
2015
Focus
Small Molecules
About
MingSight Pharmaceuticals is a clinical stage company focused on the development of a new generation of selective inhibitors of protein kinase C (PKC) for the treatment of diseases with high unmet medical needs.
Funding History
2Total raised: $45M
Series B$30MOrbiMedMar 15, 2023
Series A$15MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2015
LocationNanjing, United States
StagePhase 1/2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile